SEPIA-ACS1: Otamixaban in ACS

Links shared publicly online about this topic.

1,786
total visits

SEPIA-ACS1: Otamixaban in ACS

UPDATED // Intermediate doses of the new factor Xa inhibitor showed trends toward reduced event rates with a similar rate of bleeding compared with heparin/eptifibatide in this phase 2 study.

View full resource at theheart.org

Tags: Bleeding, Phase 2 Clinical Trial

Most Recently Shared on August 30, 2009 at 6:19 am By:

Shelley Wood

heartwire: SEPIA-ACS1 TIMI 42: Mixed results for otamixaban in ACS http://bit.ly/27E2NM

3 years ago...

Retweet

Favorite

Otamixaban Is Promising New Treatment For Patients With Acute Coronary Syndromes (SEPIA-ACS1 TIMI 42 Study)

medicalnewstoday.com — “An article published online first and in an upcoming edition of the lancet shows that otamixaban is a promising new agent for patients with acute coronary syndromes (heart attacks or sudden” View full resource at medicalnewstoday.com

Most Recently Shared on September 4, 2009 at 3:12 am By:

Heart Health Health News

MedicalNewsToday: Otamixaban Is Promising New Treatment For Patients With Acute Coronary: http://bit.ly/4h46l4 Full http://bit.ly/2RcQNh

3 years ago...

Retweet

Favorite

Otamixaban May Be A Useful Alternative Treatment For Patients With Acute Coronary Syndromes (SEPIA-ACS1 TIMI 42 Study)

medicalnewstoday.com — “An article published online first and in a future edition of the lancet reports that otamixaban is a potential new agent for patients with acute coronary syndromes, such as heart attacks or” View full resource at medicalnewstoday.com